A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.
In this retrospective study, researchers stratified pediatric AML patients by risk and aimed to determine whether some could receive fewer chemotherapy cycles without affecting relapse and survival ...
A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...
Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use ...
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback